Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

This study has been completed.
Genentech, Inc.
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Jeffrey James Olson, Emory University Identifier:
First received: September 14, 2011
Last updated: April 25, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2016
  Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)